Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.
about
Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice.Applications and implications of heparin and protamine in tissue engineering and regenerative medicine.NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker studyProtective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.Complex Inflammation mRNA-Related Response in ALS Is Region DependentInterleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.Use of biomarkers in ALS drug development and clinical trialsTocilizumab infusion therapy normalizes inflammation in sporadic ALS patients.Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients' peripheral blood.Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications.Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathwaysSerum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis.A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment.
P2860
Q27340206-14FA7C0A-61DA-4BD3-928F-1B27C4854590Q33786769-0A6D746D-7652-4226-BC4B-F1B036F26596Q33924917-D2D7334B-FBF9-4840-A8D4-89443E0F6FD8Q35501874-7DDA097F-FC71-4882-956E-11F08CCB07DAQ35957868-187A522B-65D1-4C2C-85F4-1E71C0B72C62Q35986943-1702C4CF-DDBC-4134-8B35-1EE415CBB4C7Q36733981-84E0C68D-0E47-467D-9C63-76123E303140Q36987643-F33C03F0-3002-41CD-88F0-4A00C1433E28Q38629714-BC7ED878-5A70-4CA5-B0C9-E45525710805Q39033841-5F35BF3C-9438-49C8-9738-3EA9B7D189AAQ41488070-318E19C2-93C5-4E8A-A9EC-D721AA569FA7Q41585035-21CB1E14-D479-4C8C-AD6A-8C4FE2CC43F7Q42367893-C09BD03B-B18D-4C36-BF77-2A067C7DF336Q42772755-740CAAFC-2D76-400F-8E70-090E4B1CC519Q46282864-E2E8765E-5B91-4397-A90C-06D00D8DFE0FQ50348976-02285665-C941-464E-8E7E-55F437027A6E
P2860
Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@ast
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@en
type
label
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@ast
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@en
prefLabel
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@ast
Tocilizumab attenuates inflamm ...... ion of IL6 receptor signaling.
@en
P2093
P2860
P1476
Tocilizumab attenuates inflamm ...... tion of IL6 receptor signaling
@en
P2093
Antonio La Cava
Derrick Chan
Guanghao Liu
James Sayre
Larry Magpantay
Madhuri Chattopadhyay
Mathew T Mizwicki
Milan Fiala
Najib Aziz
P2860
P304
P577
2012-11-21T00:00:00Z